The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis by Cossu, M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/171755
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Brief Communication
The magnitude of cytokine production by stimulated CD56+ cells is
associated with early stages of systemic sclerosis
Marta Cossu a,b,⁎, Lenny van Bon a, Stefan Nierkens b, Chiara Bellocchi c, Alessandro Santaniello c, Harry Dolstra d,
Lorenzo Beretta c,1, Timothy R.D.J. Radstake a,b,1
a Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
b Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
c Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
d Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
a b s t r a c ta r t i c l e i n f o
Article history:
Received 1 April 2016
Received in revised form 12 July 2016
accepted with revision 7 September 2016
Available online 9 September 2016
Immune activation is a hallmark of systemic sclerosis (SSc). However, the immunological alterations that occur in
preclinical and non-ﬁbrotic SSc and that differentiate these subjects from thosewith primary Raynaud's phenom-
enon (PRP) or healthy controls (HC) are poorly deﬁned.We isolated CD56+ (NK/NKT-like) cells fromHC, patients
with PRP, early SSc (EaSSc) and deﬁnite SSc without skin or lung ﬁbrosis. Cytokine production upon different ac-
tivating stimuliwasmeasured via amultiplex immuno assay. Clearly discriminative patterns among the different
stages of SSc were most markedly observed after TLR1/2 stimulation, with increased IL-6, TNF-α and MIP-1α/
CCL3 production in deﬁnite SSc patients as compared to HC and/or PRP. Initial alterations were observed in
EaSSc patients with an intermediate secretion pattern between HC/PRP and deﬁnite SSc. CD56+ cells from
patients at different stages of SSc differentially respond to TLR stimulation, highlighting the relevance of natural
immunity in the developmental and pre-ﬁbrotic SSc.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Systemic Sclerosis (SSc) is a multisystem disease characterized by
activation of the immune system and widespread vasculopathy culmi-
nating in ﬁbrosis of the skin and internal organs [1].Whereas Raynaud's
phenomenon (RP) usually is the ﬁrstmanifestation of disease, both vas-
culopathy aswell as activation of the immune system could precede the
diagnosis of deﬁnite SSc by years. Indeed, subjectswith RPwho test pos-
itive for SSc-speciﬁc autoantibodies and/or display typical alterations at
the nailfold videocapillaroscopy are at risk for SSc [2–4]; this condition
is therefore deﬁned as undifferentiated connective tissue disease at
risk for SSc (UCTD/SSc) [5] or early SSc (EaSSc) [6].
Innate immune system alterations have extensively been described
in established SSc with overt skin ﬁbrosis [7,8], yet little is known
about changes in natural immunity that may occur in EaSSc or in pre-
ﬁbrotic scleroderma as compared to subjects with primary Raynaud's
phenomenon (PRP). Recently, we have demonstrated that interferon
type I signatures inwhole blood are a prominent feature of SSc in its de-
velopmental phase [9] and that EaSSc distinctly have increased plasma
levels of dendritic cells (DC)-derived C-X-C motif chemokine 4
(CXCL4) [10].
Other components of the natural immunity, such as natural killer
(NK, CD56+ CD3-) and NKT-like (CD56+ CD3+) cells, may also have a
role in the development and progression of SSc. NK are able to release
a wide variety of cytokines upon different activating triggers and to
tune the maturation of other cells of the immune system, such as DC
and T cells, skewing them into a pro-inﬂammatory or tolerogenic status
or into different Th patterns of activation [11]. NKT-like cells are a broad,
diverse group of T cells co-expressing T cell receptor and NK receptors,
which cluster very close to NK cells in terms of multiparameter surface-
molecule expression, but exhibit a relative transcriptional quiescence,
requiring a more pro-inﬂammatorymilieu to exert similar immunoreg-
ulatory properties [12]. The role of NK and NKT-like cells in SSc has not
been fully clariﬁed yet, as some authors claimed a reduced number and
function of NK andNKT-like cells, whereas others suggested a normal or
increased number of NK cells in the disease alongwith an activated phe-
notype but defective killing capability, all reviewed in [13]. The current
knowledge about NK and NKT-like cells in SSc comes from studies con-
ducted on established SSc; only one recent report studied NK and NKT-
like cells also in a small group of preclinical SSc, ﬁnding nodifferences in
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the ﬂow cytometry absolute count of both NK and NKT-like cells as
compared to healthy subjects, but no further functional analyses were
performed [13].
To assesswhether functional alterations in NK andNKT-like cells can
be detected in the earliest and non-ﬁbrotic phases of SSc to differentiate
developing scleroderma from PRP, we investigated the response of
CD56+ cells to different activating stimuli in patients with long-
standing PRP, EaSSc and deﬁnite SSc yet lacking any cutaneous or pul-
monary ﬁbrotic involvement.
2. Methods
2.1. Patients and controls
Forty-six patients referring to the Scleroderma Unit of the
Fondazione IRCCS Ca′ Granda Policlinico di Milano were considered.
The study group included 10 PRP subjects according to the criteria pro-
posed in [14], 24 EaSSc patients according to LeRoy andMedsger criteria
[6] without any signs and symptoms indicative of deﬁnite disease, 12
SSc according to the 2013 ACR/EULAR criteria [2] without skin ﬁbrosis
(modiﬁed Rodnan skin score = 0) [15] and without any sign of lung ﬁ-
brosis deﬁned as a typical involvement of the lung parenchyma N5% on
high resolution computed tomography [16] accompanied by a reduced
forced vital capacity or diffusing capacity for carbon monoxide b80%
of predicted values. Nine healthy controls (HC) matched for sex and
age were also included as a comparison group. Clinical characteristics
of the study groups are shown in Table 1.
All the subjects gave their written consent to have their laboratory
and epidemiological data anonymously used for the study, which was
approved by the local ethic committee (comitato etico Area B Milano,
protocol 425/2014) and performed in accordance with the Declaration
of Helsinki.
2.2. Samples collection and analysis
Peripheral Blood Mononuclear Cells (PBMC) were isolated by
density-gradient centrifugation over ﬁcoll-Paque from heparinized ve-
nous blood. Subsequent positive selection (Miltenyi Biotec) was used
to isolate CD56+ cells from the PBMC fraction (purity N95%). 5 × 104
CD56+ cells/well were seeded in a 96-well plate in a ﬁnal volume of
100 μl and stimulated for 24 h in culture medium (Gibco® RPMI 1640
mediumwith 10% Fetal Calf Serum, 1% Penicillin-Streptomycin, 1% Glu-
tamine) with TLR agonists (5 μg/ml TLR1/2 Pam3CSK4, EMC
microcollections; 10 μg/ml TLR3 Poly(I:C) and 2 μg/ml TLR7/8 R848;
InvivoGen); additionally, CD56+ cells were stimulated with human
recombinant IL-2 (60 U/ml, R&D Systems) and IFN-α (1000 U/ml, Cell
Sciences). Cell-free supernatants were stored at−80 °C until analysis.
Levels of IL-6, TNF-α, IL-10, IFN-γ, IL-4, IL-13, IL-17, IL-22, IL-8/
CXCL8, GM-CSF, RANTES, MIP-1α/CCL3 were measured in cell-free su-
pernatants of CD56+ cells by the MultiPlex Core Facility of the Labora-
tory of Translational Immunology (LTI) with in-house-developed bead
sets as previously described [17]. For statistical analysis, concentrations
below thedetection limitwere converted to half of the lower limit of de-
tection. When N10% of measurements were below detection limit, the
mediator was excluded for further analysis, unless N90% was detected
in one speciﬁc subgroup; IFN-γ, IL-4, IL-13, IL-17 didn't respect these
prerequisites and were therefore removed before performing statistical
analysis. All the concentrations are expressed in pg/mL throughout the
paper.
2.3. Statistical analysis
All the analyses were conducted via the SPSS ver 22.0 software (IBM
Corp, ArmonkNY). Continuous variables are expressed asmean± stan-
dard deviation (SD). Comparisons were performed via one-way
ANOVA; the Levene's test was used to test the equality of variances;
when the test was not signiﬁcant (N0.05) the F-statistic was used to es-
tablish the signiﬁcance of the model, the Welch's test was used other-
wise. When ANOVA results were declared signiﬁcant at the 0.00625
level (α= 0.05/8 comparisons) post-hoc tests were used to evaluate
the signiﬁcance of pairwise comparisons, namely, the Tukey's test or
the Games-Howell test in relation to Levene's test signiﬁcance. Post-
hoc tests were then considered signiﬁcant at the 0.05 threshold. The
ANOVA polynomial linear test was used to evaluate trends for continu-
ous variables; polynomial tests were declared signiﬁcant at the 0.00625
level. To provide more robust estimates, univariate outliers, as deter-
mined by the boxplot method, were removed.
To characterize and to provide a better visualization of trends among
groups, subjects' data were also categorized: individuals whose analyte
concentrations were b1st quartile were classiﬁed as low producers; in-
dividuals with concentrations in the 1st–3rd quartile as intermediate
producers; individuals with concentrations N3rd quartile as high pro-
ducer. Categorical trends were evaluated via the Somer's D test with a
nominal signiﬁcance level as above; during categorization outliers
were not removed.
3. Results
Cytokine levels in supernatants from unstimulated CD56+ cells did
not differ among groups and no statistical trends could be observed ei-
ther (Table 2). CD56+ cell stimulation, however, not only led to a sub-
stantial increase in the amount of produced cytokines but also showed
a number of signiﬁcant trends across groups as well as a few signiﬁcant
pairwise comparisons. The data are shown in Table 2with the exception
of the ones referring to IL-10 and IL-22 production (shown in Suppl.
Table 1), whose levels were just above the detection limits in each con-
ditions applied and in all groups of patients and HC, thus providing only
arguable biological relevance. The most consistent results were ob-
served after Pam3CSK4 (TLR1/2) stimulation with a gradual increase
from HC to SSc in IL-6 (polynomial linear trend p= 2 ∗ 10−4), in TNF-
α (p = 3.47 ∗ 10−4) and in MIP-1α concentrations (p = 0.002). For
IL-6 and TNF-α, a full statistical signiﬁcance was reached comparing
the concentrations elicited in CD56+ cells from HC vs SSc or vs EaSSc,
and from PRP vs SSc subjects (ANOVA F = 0.001 and post-hoc tests
b0.05); substantial or exploratory signiﬁcance was also reached for
MIP-1α for the same comparisons (ANOVA F b 0.05 and post-hoc tests
b0.05).
Categorical analysis (summarized in Supplemental Table 2 and de-
tailed in Supplemental Tables 3–8) conﬁrmed the quantitative results
with signiﬁcant trends (Somer's D b 0.00625) observed after TLR1/2
stimulation for IL-6, TNF-α and MIP-1α (Fig. 1), as well as after TLR7/
Table 1
Baseline clinical and demographic characteristics.
HC PRP EaSSc SSc
N 9 10 24 12
Females, n (%) 8 (88.9) 10 (100) 21 (87.5) 12 (100)
Age, yrs 47.8 ± 8.4 48.9 ± 18.7 53 ± 14.9 56.2 ± 11.3
RP duration, yrs NA 22.5 ± 14.2 ⁎9.8 ± 8.7 18.4 ± 13.3
Autoantibodies, n (%)
ANA 0 (0) 0 (0) 20 (83.3) 12 (100)
ACA 0 (0) 0 (0) 13 (54.1) 9 (75)
ATA 0 (0) 0 (0) 3 (12.5) 1 (8.3)
Capillaroscopy, n (%) 0 (0) 0 (0) 18 (75) 12 (100)
Teleangectasia, n (%) 0 (0) 0 (0) 0 (0) 5 (41.7)
Puffy ﬁngers, n (%) 0 (0) 0 (0) 0 (0) 10 (83.3)
Digital ulcers, n (%) 0 (0) 0 (0) 0 (0) 2 (16.7)
HC, healthy controls; PRP, primary Raynaud's phenomenon; EaSSc, early systemic sclero-
sis; SSc, deﬁnite systemic sclerosis; N, number; yrs, years; RP, Raynaud's phenomenon;
ANA, Anti-Nuclear antibodies; ACA, Anti-Centromere antibodies; ATA, Anti-Topoisomer-
ase I antibodies; NA, not applicable. Values are expressed as mean ± standard deviation,
when not differently speciﬁed.
⁎ p b 0.05 if compared to PRP group.
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Table 2
Concentrations of analytes according to the different groups.
HC, healthy controls; PRP, primary Raynaud's phenomenon; EaSSc, early systemic sclerosis; SSc, deﬁnite systemic sclerosis. Trend p, ANOVA polynomial linear trend. ANOVA, analysis of
variance. Signiﬁcant results after Bonferroni correction (α=0.00625) are depicted as dark-shaded cells; results signiﬁcant at the exploratory 0.01 threshold are depicted as light-shaded
cells. The symbol ¶ depicts the signiﬁcant pairwise comparisons, p b 0.05 or ¶¶, p b 0.001 as compared to the SSc group; the symbol † depicts the signiﬁcant pairwise comparison, p b 0.05,
as compared to the HC group. Values are expressed in pg/mL as mean ± standard deviation.
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8 stimulation (R848) for the same analytes. As displayed in Fig. 1, after
TLR1/2 stimulation, high production of IL-6, TNF-α and MIP-1α by
CD56+ cells is mainly observed in SSc patients while in HC or PRP sub-
jects low- and/or intermediate production dominate; EaSSc show an in-
termediate activation pattern.
4. Discussion
Immune system activation is a cardinal feature of SSc that may ante-
date the onset of a full-blown ﬁbrotic disease by years [1–4]. Yet, little is
known about the ongoing autoimmune process in the preclinical stage
of SSc. From a pathogenetic point of view, autoimmune diseases are
thought to be the consequence of an environmental trigger in a geneti-
cally susceptible host, where a cascade of events leads to a chronic im-
mune response and ﬁnally breakthrough of tolerance. Under this
conceptual framework, cells of the innate immune system may have a
fundamental role in eliciting and perpetrating autoimmunity, being
the body's ﬁrst line of response.
The mechanisms at the basis of the lack of self-recognition and initi-
ation of the autoimmune response remain elusive. In particular, it is
hard to distinguish which part of the inﬂammatory response observed
in the context of autoimmune phenomena is causative and which is a
mere consequence of the process, yet perpetuating inﬂammation and
tissue damage with continued exposure of self antigens. NK cells have
been considered as decisive players in many autoimmune diseases
and suggested to play an important role in the earliest, pre-clinical
phases (reviewed in [18]). The loss of self-recognition in NK cells
could be partly due to failure to deliver inhibitory signals in the form
of a MHC class I - Killer Immunogloblulin-like Receptors (KIR) mis-
match, with inadequate dampening of the response to foreign triggers
as consequence. More recently though, the current work on NK
cells points ﬁrmly towards a disproportional, maintained activating sig-
naling in patients with different autoimmune diseases. Therefore,
hyperactivated NK cells could directly cause tissue damage by uncon-
trolled cytotoxic response but also modulate the immune response
[11], mostly after TLR stimulation [19] in the interaction with antigen-
presenting cells and T cells, via direct cell-to-cell contact or via cytokine
production. In line with this premise, we found an increased activation
of CD56+cells after TLR1/2 and to some extent after TLR7/8 stimulation
that allow a clear differentiation and separation of deﬁnitive SSc from
HC and PRP subjects. These ﬁndings are of paramount importance as
in our study we considered subjects with deﬁnite SSc yet without any
sign of advanced disease and that represent a unique population with
early signs of evolution. Interestingly, even if statistical differences in cy-
tokine concentrations between EaSSc and HC was only depicted with
regard to IL-6 secretion, upon TLR1/2 stimulation we observed also
clear increasing trends in CD56+ cells activation patterns with regard
to TNF-α and MIP-1α. These ﬁndings enforce the notion that in EaSSc
subjects vascular and immune mechanisms that will eventually lead
to the appraisal of a deﬁnite SSc are already active yet less preponderant
than in established SSc [20]. This striking trend can primarily be ob-
served for IL-6 but also for MIP-1α/CCL3 and TNF-α, which is indeed
consistent with previous observations correlating IL-6 and MIP-1α/
CCL3 levels to SSc disease progression [21]. Our group has shown that
a functionally relevant TLR2 SNP may affect IL-6 and TNF-α production
in SSc myeloid and monocyte-derived DC [22], likely through a higher
surface expression and a slowed trafﬁcking of TLR1/2. It could be hy-
pothesized that the linearly increasing pro-inﬂammatory effect that
we observed in CD56+ cells from HC and PRP to EaSSc and ultimately
to SSc patients under TLR1/2 stimulation might reﬂect a speciﬁc alter-
ation in downstream signaling in CD56+ cells. Alternatively, some of
the lipopeptidic ligands responsible for TLR1/2 activation, as opposed
to nucleic acids recognized by intracellular TLRs, might be involved
into the inﬂammatory process.
NK cells and NKT-like cells share functional capability and they both
respond to TLR triggering [23] and to the different NK receptors on the
cell surface via ligation of MHC class I molecules and stress-induced
molecules. NKT-like cells though, represent a very diverse subset of T
cells also capable of TCR-mediated and MHC-restricted activation.
CD56bright NK cells are known to be themain cytokine-producing subset
and express the highest level of TLR2 [24]. Similarly, KIR- NKT-like cells
have been shown to be more capable of cytokine production than their
KIR+ counterpart in response to different stimuli, among which TLR2
triggering [12]. The potentiated cytokine production in response to
TLR1/2 triggering described in our work could mirror a preferential ac-
tivation of the CD56bright NK compartment and/or of the KIR- NKT-like
subset in Early and more prominently in deﬁnite SSc patients.
In our study, we were not able to phenotype and differentiate be-
tween the effect exerted by NK (CD56+ CD3-) and NKT-like
(CD56+ CD3+) cells separately, and therefore additional investigations
focusing on the inﬂux and contribution of each population are currently
underway to study this inmore detail. Furthermore, it would be of great
value to assess prospectively the CD56+ pattern of activation after TLR
stimulation in EaSSc patients who evolve into SSc.
5. Conclusions
Hereinwe describe for the ﬁrst time the unique pattern of activation
of NK/NKT-like cells in the different stages of preclinical and non-
ﬁbrotic SSc. We showed that innate immune system responses can ini-
tially be altered in subjects with a diagnosis of EaSSc to be substantially
modiﬁed when signs of a deﬁnite disease are found. This ﬁnding is of
relevance as it may allow the identiﬁcation of pathways leading to
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Fig. 1. Distribution of low- intermediate- and high- IL-6, TNF-α andMIP-1α producers after TLR1-2 stimulation in relation to the diagnosis. HC, healthy controls; PRP, primary Raynaud's
phenomenon; EaSSc, early systemic sclerosis; SSc, deﬁnite systemic sclerosis. The stacked percent bar plots represent the percentage (%) of low- (white), intermediate- (grey) and high-
(black) IL-6 (A), TNF-α (B), MIP-1α (C) producers after TLR1/2 stimulation within the different patients groups.
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full-blown SSc and may give rise to the possibility of disease intercep-
tion, treating molecular aberrances before actual disease onset.
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